with VICTRELIS): If the original regimen was 0.6 mg twice a day, reduce dose to 0.3 mg once a day. If the original regimen was 0.6 mg once a day, reduce the dose to 0.3 mg once every other day.
Treatment of familial Mediterranean fever (FMF) (during treatment with VICTRELIS): Maximum daily dose of 0.6 mg (maybe given as 0.3 mg twice a day). |
|
Anti-infective: clarithromycin |
↑ clarithromycin |
Concentrations of clarithromycin may be increased with VICTRELIS; however, no dosage adjustment is necessary for patients with normal renal function. |
Antimycobacterial:
rifabutin |
↓ boceprevir
↑ rifabutin |
Increases in rifabutin exposure are anticipated, while exposure of boceprevir may be decreased. Doses have not been established for the 2 drugs when used in combination. Concomitant use is not recommended. |
|
Calcium Channel Blockers, dihydropyridine: felodipine, nifedipine, nicardipine |
↑ dihydropyridine calcium channel blockers |
Plasma concentrations of dihydropyridine calcium channel blockers may increase when administered with VICTRELIS. Caution is warranted and clinical monitoring is recommended. |
|
Corticosteroid, systemic: dexamethasone |
↓ boceprevir |
Coadministration of VICTRELIS with CYP3A4/5 inducers may decrease plasma concentrations of boceprevir, which may result in loss of therapeutic effect. Therefore, this combination should be avoided if possible and used with caution if necessary. |
|
Corticosteroid, inhaled: budesonide, fluticasone |
↑ budesonide
↑ fluticasone |
Concomitant use of inhaled budesonide or fluticasone with VICTRELIS may result in increased plasma concentrations of budesonide or fluticasone, resulting in significantly reduced serum cortisol concentrations. Avoid coadministration if possible, particularly for extended durations. |
|
Endothelin Receptor Antagonist: bosentan |
↑ bosentan |
Concentrations of bosentan may be increased when coadministered with VICTRELIS. Use with caution and monitor closely. |
|
HIV Non-Nucleoside Reverse Transcriptase Inhibitors: efavirenz |
↓ boceprevir* |
Plasma trough concentrations of boceprevir were decreased when VICTRELIS was coadministered with efavirenz, which may result in loss of therapeutic effect. Avoid combination |
|
HIV Protease Inhibitors: ritonavir |
↓ boceprevir*
↑ or ↓ HIV protease inhibitors |
Boceprevir concentrations decreased with ritonavir; the effect of ritonavir-boosted HIV protease inhibitors on boceprevir exposure is unknown. The effect of VICTRELIS on HIV protease inhibitor concentrations is unknown. |
|
HMG-CoA Reductase Inhibitors: atorvastatin |
↑ atorvastatin |
Titrate atorvastatin dose carefully and do not exceed maximum daily dose of 20 mg during coadministration with VICTRELIS |
|
Immunosuppressants: cyclosporine, sirolimus, tacrolimus |
↑immunosuppressants |
Plasma concentrations of cyclosporine, sirolimus and tacrolimus are expected to be increased significantly during coadministratio |
